Tiziana Announces Positive Clinical Data from A Secondary Progressive Multiple Sclerosis Patient Treated for Six Months with Intranasally Administered Foralumab, A Fully Human Anti-CD3 Monoclonal Antibody
Intranasal foralumab was well-tolerated with no adverse reactions or laboratory abnormalities after 6 months of…